Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2540 - Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial

Date

09 Sep 2017

Session

Poster display session

Presenters

Michael Teufel

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

M. Teufel1, H. Seidel2, K. Köchert3, G. Meinhardt4, R.S. Finn5, J.M. Llovet6, J. Bruix7

Author affiliations

  • 1 Translational Medicine Oncology, Bayer HealthCare Pharmaceuticals, 07981 - Whippany/US
  • 2 Bioinformatics, Bayer AG, 13342 - Berlin/DE
  • 3 Genomics And Biomarker Statistics, Bayer AG, 13353 - Berlin/DE
  • 4 Clinical Development Oncology, Bayer HealthCare Pharmaceuticals, 07981 - Whippany/US
  • 5 Division Of Hematology/oncology, David Geffen School of Medicine at UCLA, 90404 - Los Angeles/US
  • 6 Liver Cancer Program, Division Of Liver Diseases, Icahn School of Medicine at Mount Sinai, 10029 - New York/US
  • 7 Bclc Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, 8036 - Barcelona/ES
More

Resources

Abstract 2540

Background

REG improved overall survival (OS) and time to progression (TTP) versus placebo in patients with HCC who progressed during prior sorafenib in the phase 3 RESORCE trial (Bruix et al, Lancet 2017). This exploratory analysis evaluated the potential of circulating miRNA plasma biomarkers to predict the OS and TTP benefit with REG in RESORCE.

Methods

Valid biomarker data were available for 343/573 patients. Expression levels of 750 plasma miRNAs collected at baseline were quantified by qPCR. To be eligible, miRNAs had to be measurable on a continuous scale or dichotomized by pre-processing (present vs absent), and present in ≥ 5% of patients (i.e. n ≥ 18). The predictive and prognostic effects (HR and 95% CI) were evaluated using a Cox proportional hazards model with miRNAs as continuous or dichotomized variables. A predictive effect was modeled as an miRNA–treatment interaction effect and subjected to Akaike information criterion (AIC)-based selection to assess its association with OS and TTP.

Results

Demographic covariates were generally similar in the overall RESORCE and miRNA biomarker cohorts, except the latter had a smaller proportion of Asian patients. Of the 750 miRNAs analyzed, 25 showed a multiplicity-adjusted prognostic effect (P ≤ 0.05) for OS. Nine miRNAs showed a multiplicity-adjusted predictive effect (P ≤ 0.05) for OS; 3 of the 9 predictive markers were also prognostic (Table). No miRNA was found to be predictive for TTP.Table:

705P

miRNAmiRNA predictive for OSmiRNA prognostic for OS
HR (95% CI)P-valueP-value
hsa-miR-15b-3p0.37 (0.20, 0.70)≤0.050.01
hsa-miR-1070.54 (0.37, 0.81)≤0.050.06
hsa-miR-320b0.57 (0.41, 0.81)≤0.050.01
hsa-miR-122-5p1.35 (1.14, 1.60)≤0.050.39
hsa-miR-374b-3p1.36 (1.11, 1.65)≤0.050.06
hsa-miR-200a-3p1.39 (1.15, 1.68)≤0.050.03
hsa-miR-30a-5p1.47 (1.14, 1.88)≤0.050.34
hsa-miR-125b-5p1.54 (1.19, 1.99)≤0.050.32
hsa-miR-6453.16 (1.52, 6.55)≤0.050.06

Conclusions

This exploratory analysis suggests that multiple miRNAs may be potentially predictive for OS in patients treated with REG. The biological role of the miRNAs in HCC as well as their potential functional correlation to treatment benefit needs to be analyzed further.

Clinical trial identification

NCT01774344

Legal entity responsible for the study

Bayer

Funding

Bayer

Disclosure

M. Teufel, G. Meinhardt: Stocks and Employment: Bayer. H. Seidel, K. Köchert: Employment: Bayer. R.S. Finn: Consulting and Advisory Role: Bayer, Pfizer, Novartis, BMS, Eisai. J.M. Llovet: Research/Education Grant: Bayer, Blueprint Medicines, BI, Incyte Advisory Board: Bayer, Eisai, BMS, Eli Lilly Consulting: Eli Lilly, Bayer, BMS, Blueprint Medicines, Eisai, Celsion, BI. J. Bruix: Research/Education Grant: Daiichi Sankyo, ArQule, Bayer, Sirtex. Honoraria: Gilead, AbbVie, Kowa, Bayer, BTG, ArQule, Terumo, Sirtex, BMS, Eisai, BI, Novartis, OSI, Roche, Onxeo. Advisory Board: Bayer, Kowa, BTG, ArQule, Terumo, Sirtex, BMS, Eisai, Novartis, OSI, Roche, Onxeo. Consulting: Gilead, AbbVie, Kowa, Bayer, BTG, ArQule, Terumo, Sirtex, BMS, BI, Kowa, Novartis, OSI, Roche, Onxeo, Daiichi Sankyo, Abbot, Glaxo, Eli Lilly.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.